Cancer nanomedicine: Is targeting our target?

Twan Lammers; Fabian Kiessling; Marianne Ashford; Wim Hennink; Daan Crommelin; G Storm

doi:10.1038/natrevmats.2016.69

Cancer nanomedicine: Is targeting our target?

Twan Lammers, Fabian Kiessling, Marianne Ashford, Wim Hennink, Daan Crommelin, G Storm

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Nanomedicine may have a delivery problem. Rigorous, realistic and holistic rethinking is needed to improve nanomedicine performance and increase patient benefit.

Original language	English
Journal	Nature Materials
Volume	1
Issue number	9
DOIs	https://doi.org/10.1038/natrevmats.2016.69
Publication status	Published - Sept 2016

Access to Document

10.1038/natrevmats.2016.69

Cite this

@article{66bdc2dde0594015ae063510edfd9bd0,

title = "Cancer nanomedicine: Is targeting our target?",

abstract = "Nanomedicine may have a delivery problem. Rigorous, realistic and holistic rethinking is needed to improve nanomedicine performance and increase patient benefit.",

author = "Twan Lammers and Fabian Kiessling and Marianne Ashford and Wim Hennink and Daan Crommelin and G Storm",

year = "2016",

month = sep,

doi = "10.1038/natrevmats.2016.69",

language = "English",

volume = "1",

journal = "Nature Materials",

issn = "1476-1122",

publisher = "Nature Publishing Group SN -",

number = "9",

}

TY - JOUR

T1 - Cancer nanomedicine

T2 - Is targeting our target?

AU - Lammers, Twan

AU - Kiessling, Fabian

AU - Ashford, Marianne

AU - Hennink, Wim

AU - Crommelin, Daan

AU - Storm, G

PY - 2016/9

Y1 - 2016/9

N2 - Nanomedicine may have a delivery problem. Rigorous, realistic and holistic rethinking is needed to improve nanomedicine performance and increase patient benefit.

AB - Nanomedicine may have a delivery problem. Rigorous, realistic and holistic rethinking is needed to improve nanomedicine performance and increase patient benefit.

U2 - 10.1038/natrevmats.2016.69

DO - 10.1038/natrevmats.2016.69

M3 - Article

C2 - 27668091

SN - 1476-1122

VL - 1

JO - Nature Materials

JF - Nature Materials

IS - 9

ER -

Cancer nanomedicine: Is targeting our target?

Abstract

Access to Document

Fingerprint

Cite this